Biopolicy Innovations Inc. (d.b.a. Policy Reporter)

TrialCard Inc. a portfolio company of Odyssey Investment Partners LLC has acquired Biopolicy Innovations Inc.

TrialCard Inc. (a portfolio company of Odyssey Investment Partners LLC) has acquired Biopolicy Innovations Inc. (d.b.a. Policy Reporter).

Industry:

Information Technology

TrialCard Inc. (a portfolio company of Odyssey Investment Partners LLC) has acquired Biopolicy Innovations Inc. (d.b.a. Policy Reporter). MNP Corporate Finance Inc. acted as the exclusive financial advisor to Biopolicy Innovations Inc. (d.b.a. Policy Reporter) in structuring and negotiating this transaction.

Transaction Brief

This transaction allowed the shareholder to realize a significant liquidation event while continuing to participate in the growth of the business moving forward.

Founded in 2012, Policy Reporter is a healthcare information management company specializing in increasing patient access to pharmaceuticals, biologics, medical devices, and diagnostic testing.

TrialCard Inc. is a healthcare technology business that provides patient affordability, medication access and adherence, patient support, and clinical trial services on behalf of pharmaceutical manufacturers. Founded in 2000, TrialCard has connected over 30 million patients with nearly $12 billion in branded drug savings to date. The company is headquartered in Morrisville, North Carolina and is majority owned by private equity firm Odyssey Investment Partners. Odyssey Investment Partners, based out of New York City, has raised over $5.0B of private equity capital since inception and is currently investing out of their $2.0B fifth fund.